Skip to Content
Merck
CN

O2881

Oxybutynin chloride

≥98% (TLC), Muscarinic acetylcholine receptor antagonist, powder

Synonym(s):

α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H31NO3 · HCl
CAS Number:
1508-65-2
Molecular Weight:
393.95
NACRES:
NA.77
PubChem Substance ID:
57654480
UNSPSC Code:
12352200
EC Number:
216-139-7
MDL number:
MFCD00072150

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Oxybutynin chloride, ≥98% (TLC), powder

Quality Level

200

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

assay

≥98% (TLC)

form

powder

color

white

solubility

H2O: 50 mg/mL

originator

Johnson & Johnson

Gene Information

human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist.
Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000391642
0000391642
0000276178
0000276177
0000276178

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Theodore M Johnson et al.
BJU international, 112(1), 100-108 (2013-03-02)
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Nocturia is a common and bothersome lower urinary tract symptom, particularly in men. Many single drug therapies have limited benefit. For men who have persistent nocturia despite alpha-blocker therapy
P Tauzin-Fin et al.
Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)
Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in
R Cremer
Der Urologe. Ausg. A, 51(7), 991-995 (2012-06-15)
Paraplegic spina bifida patients often suffer from disturbed sweat secretion in the paretic regions. A diminished sweat production of caudal parts of the body is compensated by an increased secretion of sweat in parts cranial to the lesion to maintain
Naoki Aizawa et al.
European urology, 62(6), 1165-1173 (2012-09-18)
Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats
Daniele Zama et al.
Pediatric transplantation, 17(1), 86-91 (2012-12-13)
HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service